Skip to main content

Studer Orthotopic Ileal Neobladder

The Studer neobladder is the most commonly performed orthotopic neobladder technique worldwide, used in approximately 74% of intracorporeal neobladder reconstructions following radical cystectomy.[1][2] Developed by Urs Studer at the University of Bern in 1996, it is distinguished by an isoperistaltic afferent ileal limb that provides a simple, non-refluxing ureteroileal anastomosis without a formal antireflux mechanism.[3][4] Together with the Hautmann ileal neobladder (Ulm), the Studer technique is one of the two dominant orthotopic reconstruction methods worldwide; the two centers have collectively performed > 1,300 neobladders.[4]

Anatomy​

Two functional components — both constructed entirely from ileum:[5][6]

  • Reservoir (pouch) — ~ 40 cm of detubularized ileum opened along the antimesenteric border and folded into a roughly spheroidal U-shape, creating a low-pressure high-capacity reservoir
  • Afferent isoperistaltic limb — 15–20 cm of intact (non-detubularized) ileum in continuity with the reservoir, into which the ureters are implanted with a simple end-to-side (Nesbit) anastomosis

The reservoir is anastomosed distally to the native urethra, allowing voiding per urethra without a stoma. The afferent limb's isoperistaltic contractions propel urine toward the reservoir and resist retrograde flow — a passive functional antireflux mechanism that eliminates the need for a formal antireflux anastomosis (which historically carried higher stricture rates).[3][7][4]

Studer orthotopic neobladder: a detubularized ileal sphere anastomosed to the urethra at its most dependent point, with an intact afferent limb receiving the ureters

The Studer configuration. The distal ileum is detubularized and cross-folded into a spheroidal low-pressure reservoir, anastomosed to the native urethra at its most dependent point; the proximal 15–20 cm stays intact as the isoperistaltic afferent (Studer) limb that receives both ureters (Nesbit end-to-side). The inset shows why detubularization is essential — opening and re-folding the bowel breaks the peristaltic contraction waves and, by the law of Laplace, drops storage pressure, protecting the kidneys and enabling continence. (Original WARWIKI schematic)

Surgical Technique​

  1. Ileal segment isolation — total 55–65 cm of distal ileum with mesenteric blood supply preserved; distal end ~ 15–25 cm proximal to the ileocecal valve
  2. Bowel continuity restoration — ileoileal anastomosis (stapled or hand-sewn)
  3. Afferent limb designation — proximal 15–20 cm kept intact (not detubularized)
  4. Detubularization — distal 40–45 cm opened along the antimesenteric border
  5. Reservoir construction — detubularized segment folded (U or W) and edges sutured into a spheroidal pouch; most dependent (conic) portion designated for the urethral anastomosis
  6. Neovesicourethral anastomosis — lowest point of reservoir to urethral stump with interrupted sutures over a catheter
  7. Ureteroileal anastomosis — both ureters spatulated and anastomosed end-to-side to the afferent limb (Nesbit) over ureteral stents
  8. Fixation (modified) — neobladder anchored to levator ani; afferent limb to psoas for stabilization[5]

Open vs robotic intracorporeal​

  • First completely intracorporeal laparoscopic Studer neobladder: Gill 2002[6]
  • Robotic intracorporeal techniques have evolved to reduce operative time from ~ 450 → ~ 360 min[8]
  • Piramide 2024 SR of 9 robotic intracorporeal neobladder techniques — comparable perioperative outcomes; Studer / Wiklund most commonly performed (74%)[1][2]

The Antireflux Question — USC-STAR RCT​

The central design question is whether the passive isoperistaltic limb is sufficient. The USC-STAR randomized trial (Skinner 2015, n = 484) compared the Studer pouch (freely refluxing afferent limb) to the T-pouch (formal antireflux mechanism):[10]

  • No difference in renal-function decline at 3 yr (eGFR decrease 6.4 vs 6.6 mL/min/1.73 m², p = 0.35)
  • No difference in UTI rates or overall late complications
  • T-pouch associated with more secondary diversion-related surgeries
  • Independent predictors of renal-function decline: baseline eGFR, age, urinary-tract obstruction — not neobladder type

Zhu 2025 propensity-matched comparison of formal ileum-valve-pouch antireflux vs modified Studer found similar overall complications but potentially better 12-month renal function preservation with the antireflux design — the question remains under investigation.[11]

Urodynamic Properties​

Detubularization disrupts coordinated peristalsis and creates a low-pressure system. Capacity increases and pressure decreases over the first 1–2 yr as the bowel segment adapts; parameters remain stable from 12 mo through > 10 yr.[12][13][9][14][15][7][16]

ParameterValueTime point
Maximum capacity330–495 mL12–60 mo
Pressure at max capacity10–25 cmH₂O12–60 mo
Compliance35.5 mL/cmH₂O (mean)12 mo
Maximum flow rate13.6–15.7 mL/sec> 12 mo
Post-void residual35–147 mLVariable

Functional Outcomes — Continence​

Daytime continence: 86–99%[1][12][17][13][14][4]

  • Multi-institutional RARC (n=732): 86% at 12 mo (including 20% using safety pad)[1]
  • Three-center series (n=104, median 88 mo): 98%[17]
  • Long-term (> 10 yr): 89%[13]

Nighttime continence: 66–83%

  • Improves with time: 74% at 1 yr → 83% at 2 yr[12]
  • Multi-institutional RARC: 66% at 12 mo[1]
  • Long-term (> 10 yr): 63%[13]

Pad use — Ahmadi 2013 patient-reported questionnaire: only 22.3% no pads at all; daytime ≥ 1 pad in 47%; nighttime pads 72%, diapers 39%; mucus leakage in 62.5%.[19]

Clean intermittent self-catheterization — 5–28% of patients, most initiating within the first year; rate decreases with longer follow-up (0% at > 20 yr in the Ulm series).[13][19][9][14][18]

Voiding mechanism​

The neobladder lacks the muscular ability to contract. Patients void by:[20][3]

  • Relaxing the external urethral sphincter (pelvic-floor relaxation)
  • Valsalva maneuver (abdominal straining)
  • Timed voiding every 1–3 hr initially with intervals lengthening as capacity grows
  • 87% void spontaneously and residual-free in long-term FU (decreasing with age)[18]

Complications​

Early (within 90 days) — Hautmann 1,000-neobladder series[21]​

58% experienced ≥ 1 complication within 90 days:

  • Infectious 24%, GU 17%, GI 15%, wound 9%
  • Minor (Clavien 1–2) 36%; major (Clavien 3–5) 22%
  • 90-day mortality 2.3%
  • Severity correlated with age, tumor stage, ASA, and comorbidity

Late (> 90 days) — Hautmann 25-yr 923-pt series[22]​

Overall long-term complication rate 40.8%; 3 neobladder-related deaths. 20-year cumulative incidence:

ComplicationIncidence
Hydronephrosis16.9%
Incisional hernia6.4%
Febrile UTI5.7%
Ileus / SBO3.6%
Subneovesical obstruction3.1%
Neovesicourethral anastomotic stricture1.2%
Chronic diarrhea~ 1%
Inguinal hernia12.8% (within 2 yr)[14]
Renal atrophy31.6% (> 10 yr)[13]
Chronic pyelonephritis26.3% (> 10 yr)[13]
Bladder-neck stricture requiring CIC10.5% (> 10 yr)[13]

Studer-specific complications:

  • Inguinal hernia in 12.8% — most within 2 yr; attributed to abdominal straining during voiding[14]
  • Mucus production can cause urinary retention requiring periodic irrigation; diminishes over time (0% at > 20 yr)[18]

Metabolic Consequences​

As with all bowel-based diversions:[23][18][22][24]

  • Hyperchloremic metabolic acidosis — long-term bicarbonate substitution required in 33% of patients (307/923 Ulm); rate decreased from 51% at 5 yr to 19% at 25 yr[18][22]
  • Vitamin B12 deficiency — clinically significant deficiency rare (~ 0.2–20% depending on series and ileal length used)[23][22]
  • Creatinine reabsorption across intestinal mucosa — serum creatinine unreliable; nuclear GFR scanning preferred[24]

For pharmacologic management see Vitamin B12 supplementation, Urinary acidifiers & alkalinizers, and Mucus management.

Renal function long-term[10][13][18][11][4]​

  • USC-STAR: eGFR declined 6.4 mL/min/1.73 m² over 3 yr with Studer pouch
  • Ulm 35-yr series: serum creatinine showed only age-related increases
  • > 10 yr: 31.6% renal atrophy, 26.3% moderate hydronephrosis[13]
  • Strongest predictors of decline: baseline eGFR and urinary-tract obstruction[10]

Patient Selection​

Absolute contraindications[4][25][24]​

  • Stress urinary incontinence or damaged rhabdosphincter
  • Severely impaired renal function (Cr > 2 mg/dL — though Ranti 2022 suggests CKD 3B may not be absolute[26])
  • Severe hepatic dysfunction
  • Severe intestinal disease (IBD, short-bowel syndrome)
  • Requirement for simultaneous urethrectomy (positive urethral margin)

Relative contraindications[25][24][27]​

  • Mental impairment / inability to perform CIC
  • Recurrent urethral strictures
  • Advanced age with social isolation
  • Prior pelvic radiation (relative)

Oncologic considerations[28][29][30]​

  • Tumor at the bladder neck or prostatic urethra increases urethral-recurrence risk
  • Intraoperative frozen section of urethral margin is mandatory
  • Urethral recurrence rate 1.5–5.6% overall; 31.3% with positive pre-cystectomy prostatic-urethral biopsies (most managed conservatively)[4][29]
  • Orthotopic neobladder feasible in women with negative bladder-neck frozen sections[30]

QoL — Studer vs Ileal Conduit​

Meta-analyses consistently show marginally better QoL with neobladder for physical / role / social functioning and global health,[31][32][33][34] but the picture is nuanced:

  • Neobladder patients have more urinary symptoms (incontinence, mucus leakage, pads)[31][35][36]
  • When matched for age and comorbidities, global health is often similar[37][35]
  • IC patients report better long-term urinary function[36]
  • In women, no significant QoL difference between IC and neobladder[38]
  • 96% of neobladder patients would choose the same diversion again[39]

Studer vs Other Neobladder Techniques​

FeatureStuderHautmann (W-pouch)T-PouchY-Pouch
Ileum used55–65 cm60–70 cm~ 65 cm~ 55 cm
Afferent limbYes (15–20 cm)No (direct implantation)Yes (antireflux)No
Antireflux mechanismPassive (isoperistaltic limb)Formal (Le Duc / serous-lined tunnel)Formal (tapered limb)None
Detubularization folds2 (U-shape)4 (W-shape)22 (Y-shape)
Daytime continence86–99%87–100%SimilarSimilar
Nighttime continence66–83%80–82%SimilarSimilar
Renal-function preservationGoodGoodNo advantage over StuderSimilar
Secondary surgeriesLowerSimilarHigher than StuderSimilar
Popularity (robotic)74%4%RareRare

USC-STAR demonstrated that the Studer pouch achieves equivalent renal-function preservation to T-pouch with fewer secondary surgeries — supporting the simplicity-advantage rationale for the passive afferent limb.[10] Piramide 2024 SR found no evidence favoring one robotic intracorporeal technique over another for perioperative outcomes.[2]

Long-Term Surveillance​

Lifelong follow-up is essential:[18][22][4][24][28][40]

  • Renal function — nuclear GFR preferred over serum creatinine; 3 / 6 / 12 mo then annually
  • Upper-tract imaging — ultrasound or CT for hydronephrosis, stones, and upper-tract recurrence (2–3.5%)
  • Metabolic monitoring — bicarbonate, chloride, vitamin B12 annually
  • Urethral surveillance — cytology / washings for recurrence (especially with risk factors)
  • Neobladder assessment — PVR, uroflowmetry
  • Cancer surveillance — CT C/A/P per post-cystectomy protocol
  • Mucus management — patient education on irrigation

See Also​

Videos​

The Modified Studer Ileal Neobladder
Neobladder (2014)

References​

1. Martini A, Falagario UG, Russo A, et al. "Robot-assisted radical cystectomy with orthotopic neobladder reconstruction: techniques and functional outcomes in males." Eur Urol. 2023;84(5):484–490. doi:10.1016/j.eururo.2023.04.009

2. Piramide F, Turri F, Amparore D, et al. "Atlas of intracorporeal orthotopic neobladder techniques after robot-assisted radical cystectomy and systematic review of clinical outcomes." Eur Urol. 2024;85(4):348–360. doi:10.1016/j.eururo.2023.11.017

3. Cody JD, Nabi G, Dublin N, et al. "Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy." Cochrane Database Syst Rev. 2012;(2):CD003306. doi:10.1002/14651858.CD003306.pub2

4. Hautmann RE, Volkmer BG, Schumacher MC, Gschwend JE, Studer UE. "Long-term results of standard procedures in urology: the ileal neobladder." World J Urol. 2006;24(3):305–314. doi:10.1007/s00345-006-0105-z

5. Bianchi G, Sighinolfi MC, Pirola GM, Micali S. "Studer orthotopic neobladder: a modified surgical technique." Urology. 2016;88:222–225. doi:10.1016/j.urology.2015.11.020

6. Gill IS, Kaouk JH, Meraney AM, et al. "Laparoscopic radical cystectomy and continent orthotopic ileal neobladder performed completely intracorporeally: the initial experience." J Urol. 2002;168(1):13–18.

7. Minervini R, Morelli G, Fontana N, Minervini A, Fiorentini L. "Functional evaluation of different ileal neobladders and ureteral reimplantation techniques." Eur Urol. 1998;34(3):198–202. doi:10.1159/000019712

8. Chopra S, de Castro Abreu AL, Berger AK, et al. "Evolution of robot-assisted orthotopic ileal neobladder formation: a step-by-step update to the USC technique." BJU Int. 2017;119(1):185–191. doi:10.1111/bju.13611

9. Kraft P, Schregel C, Obrecht F, et al. "Reinforcing expectations after robot-assisted intracorporeal orthotopic neobladder: long-term functional, urodynamic and metabolic outcome." World J Urol. 2025;43(1):437. doi:10.1007/s00345-025-05821-z

10. Skinner EC, Fairey AS, Groshen S, et al. "Randomized trial of Studer pouch versus T-pouch orthotopic ileal neobladder in patients with bladder cancer." J Urol. 2015;194(2):433–439. doi:10.1016/j.juro.2015.03.101

11. Zhu Z, Zhu Y, Ying W, et al. "Comparison of the anti-reflux ileum valve-pouch orthotopic neobladder and the Studer technique after radical cystectomy: surgical and renal functional outcomes." World J Surg Oncol. 2025;23(1):359. doi:10.1186/s12957-025-03699-0

12. Cancrini A, De Carli P, Pompeo V, et al. "Lower urinary tract reconstruction following cystectomy: experience and results in 96 patients using the orthotopic ileal bladder substitution of Studer et al." Eur Urol. 1996;29(2):204–209.

13. Nam JK, Kim TN, Park SW, Lee SD, Chung MK. "The Studer orthotopic neobladder: long-term (> 10 yr) functional outcomes, urodynamic features, and complications." Yonsei Med J. 2013;54(3):690–695. doi:10.3349/ymj.2013.54.3.690

14. Tanaka T, Kitamura H, Takahashi A, et al. "Long-term functional outcome and late complications of Studer's ileal neobladder." Jpn J Clin Oncol. 2005;35(7):391–394. doi:10.1093/jjco/hyi112

15. Boonchai S, Tanthanuch M, Bejrananda T. "Comparison of the Y-pouch orthotopic neobladder and the Studer technique after radical cystectomy: surgical and functional outcomes from a single-center series." World J Surg Oncol. 2023;21(1):218. doi:10.1186/s12957-023-03112-8

16. Carini M, Serni S, Scelzi S, et al. "Orthotopic ileal bladder: clinical, urodynamic and metabolic evaluation." Eur Urol. 1992;22(2):99–105. doi:10.1159/000474733

17. Meyer JP, Blick C, Arumainayagam N, et al. "A three-centre experience of orthotopic neobladder reconstruction after radical cystectomy: revisiting the initial experience, and results in 104 patients." BJU Int. 2009;103(5):680–683. doi:10.1111/j.1464-410X.2008.08204.x

18. Hautmann RE, Volkmer B, Egghart G, et al. "Functional outcome and complications following ileal neobladder reconstruction in male patients without tumor recurrence: more than 35 years of experience from a single center." J Urol. 2021;205(1):174–182. doi:10.1097/JU.0000000000001345

19. Ahmadi H, Skinner EC, Simma-Chiang V, et al. "Urinary functional outcome following radical cystoprostatectomy and ileal neobladder reconstruction in male patients." J Urol. 2013;189(5):1782–1788. doi:10.1016/j.juro.2012.11.078

20. Khosla AA, Mendhiratta N, Jatwani K. "Urinary diversion after cystectomy for bladder cancer." JAMA Oncol. 2025. doi:10.1001/jamaoncol.2025.3644

21. Hautmann RE, de Petriconi RC, Volkmer BG. "Lessons learned from 1,000 neobladders: the 90-day complication rate." J Urol. 2010;184(3):990–994. doi:10.1016/j.juro.2010.05.037

22. Hautmann RE, de Petriconi RC, Volkmer BG. "25 years of experience with 1,000 neobladders: long-term complications." J Urol. 2011;185(6):2207–2212. doi:10.1016/j.juro.2011.02.006

23. Rogers E, Scardino PT. "A simple ileal substitute bladder after radical cystectomy: experience with a modification of the Studer pouch." J Urol. 1995;153(5):1432–1438. doi:10.1016/s0022-5347(01)67422-6

24. Broderick GA, Stone AR, deVere White R. "Neobladders: clinical management and considerations for patients receiving chemotherapy." Semin Oncol. 1990;17(5):598–605.

25. Jacobs BL, Lee CT, Montie JE. "Bladder cancer in 2010: how far have we come?" CA Cancer J Clin. 2010;60(4):244–272. doi:10.3322/caac.20077

26. Ranti D, Pfail J, Garcia M, et al. "Neobladder creation in patients with chronic kidney disease: a viable diversion strategy." Urol Oncol. 2022;40(4):168.e21–168.e27. doi:10.1016/j.urolonc.2021.11.023

27. Minervini A, Serni S, Vittori G, et al. "Current indications and results of orthotopic ileal neobladder for bladder cancer." Expert Rev Anticancer Ther. 2014;14(4):419–430. doi:10.1586/14737140.2014.867235

28. Stenzl A, Bartsch G, Rogatsch H. "The remnant urothelium after reconstructive bladder surgery." Eur Urol. 2002;41(2):124–131. doi:10.1016/s0302-2838(01)00031-8

29. Roth B, Furrer MA, Giannakis I, et al. "Positive pre-cystectomy biopsies of the prostatic urethra or bladder neck do not necessarily preclude orthotopic bladder substitution." J Urol. 2019;201(5):909–915. doi:10.1097/JU.0000000000000034

30. Stein JP, Penson DF, Wu SD, Skinner DG. "Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature." J Urol. 2007;178(3 Pt 1):756–760. doi:10.1016/j.juro.2007.05.013

31. Shi H, Yu H, Bellmunt J, et al. "Comparison of HRQoL between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis." Qual Life Res. 2018;27(11):2759–2775. doi:10.1007/s11136-018-1902-8

32. Singh V, Yadav R, Sinha RJ, Gupta DK. "Prospective comparison of QoL outcomes between ileal conduit urinary diversion and orthotopic neobladder reconstruction after radical cystectomy: a statistical model." BJU Int. 2014;113(5):726–732. doi:10.1111/bju.12440

33. Ghosh A, Somani BK. "Recent trends in postcystectomy HRQoL favors neobladder diversion: systematic review of the literature." Urology. 2016;93:22–26. doi:10.1016/j.urology.2015.12.079

34. Cerruto MA, D'Elia C, Siracusano S, et al. "Systematic review and meta-analysis of non-RCTs on HRQoL after radical cystectomy using validated questionnaires: better results with orthotopic neobladder versus ileal conduit." Eur J Surg Oncol. 2016;42(3):343–360. doi:10.1016/j.ejso.2015.10.001

35. Cerruto MA, D'Elia C, Siracusano S, et al. "HRQoL after radical cystectomy: a cross-sectional study with matched-pair analysis on ileal conduit vs ileal orthotopic neobladder." Urology. 2017;108:82–89. doi:10.1016/j.urology.2017.06.022

36. Gellhaus PT, Cary C, Kaimakliotis HZ, et al. "Long-term HRQoL outcomes following radical cystectomy." Urology. 2017;106:82–86. doi:10.1016/j.urology.2017.03.053

37. Kern SQ, Speir RW, Tong Y, et al. "Longitudinal HRQoL after open radical cystectomy: comparison of ileal conduit, Indiana pouch, and orthotopic neobladder." Urology. 2021;152:184–189. doi:10.1016/j.urology.2020.12.036

38. Xing W, Zeng S, Xu Z, Xing S, Liu Q. "Comparison of HRQoL between ileal conduit diversion and orthotopic neobladder in women: a meta-analysis." Front Oncol. 2022;12:862884. doi:10.3389/fonc.2022.862884

39. Dutta SC, Chang SC, Coffey CS, et al. "Health-related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder." J Urol. 2002;168(1):164–167.

40. Kubota H, Takahashi S, Monzawa S, et al. "Pictorial review of orthotopic neobladder reconstruction: indication, normal postsurgical anatomy, and complications." Abdom Radiol (NY). 2016;41(2):356–367. doi:10.1007/s00261-015-0576-8